Rescue of common exon-skipping mutations in cystic fibrosis with modified U1 snRNAs.
RNA therapies
alternative splicing
personalized medicine
theranostics
Journal
Human mutation
ISSN: 1098-1004
Titre abrégé: Hum Mutat
Pays: United States
ID NLM: 9215429
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
10
07
2020
revised:
31
08
2020
accepted:
07
09
2020
pubmed:
17
9
2020
medline:
26
11
2021
entrez:
16
9
2020
Statut:
ppublish
Résumé
In cystic fibrosis (CF), the correction of splicing defects represents an interesting therapeutic approach to restore normal CFTR function. In this study, we focused on 10 common mutations/variants 711+3A>G/C, 711+5G>A, TG13T3, TG13T5, TG12T5, 1863C>T, 1898+3A>G, 2789+5G>A, and 3120G>A that induce skipping of the corresponding CFTR exons 5, 10, 13, 16, and 18. To rescue the splicing defects we tested, in a minigene assay, a panel of modified U1 small nuclear RNAs (snRNAs), named Exon Specific U1s (ExSpeU1s), that was engineered to bind to intronic sequences downstream of each defective exon. Using this approach, we show that all 10 splicing mutations analyzed are efficiently corrected by specific ExSpeU1s. Using complementary DNA-splicing competent minigenes, we also show that the ExspeU1-mediated splicing correction at the RNA level recovered the full-length CFTR protein for 1863C>T, 1898+3A>G, 2789+5G>A variants. In addition, detailed mutagenesis experiments performed on exon 13 led us to identify a novel intronic regulatory element involved in the ExSpeU1-mediated splicing rescue. These results provide a common strategy based on modified U1 snRNAs to correct exon skipping in a group of disease-causing CFTR mutations.
Substances chimiques
RNA, Small Nuclear
0
U1 small nuclear RNA
0
Cystic Fibrosis Transmembrane Conductance Regulator
126880-72-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2143-2154Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Abbink, T. E. M., & Berkhout, B. (2008). RNA structure modulates splicing efficiency at the human immunodeficiency virus type 1 major splice donor. Journal of Virology, 82(6), 3090-3098. https://doi.org/10.1128/JVI.01479-07
Aissat, A., de Becdelièvre, A., Golmard, L., Vasseur, C., Costa, C., Chaoui, A., Martin, N., Costes, B., Goossens, M., Girodon, E., Fanen, P., & Hinzpeter, A. (2013). Combined computational-experimental analyses of CFTR exon strength uncover predictability of exon-skipping level. Human Mutation, 34(6), 873-881. https://doi.org/10.1002/humu.22300
Alanis, E. F., Pinotti, M., Mas, A. D., Balestra, D., Cavallari, N., Rogalska, M. E., Bernardi, F., & Pagani, F. (2012). An exon-specific U1 small nuclear RNA (snRNA) strategy to correct splicing defects. Human Molecular Genetics, 21(11), 2389-2398. https://doi.org/10.1093/hmg/dds045
Ayala, Y. M., Pagani, F., & Baralle, F. E. (2006). TDP43 depletion rescues aberrant CFTR exon 9 skipping. FEBS Letters, 580(5), 1339-1344. https://doi.org/10.1016/j.febslet.2006.01.052
Balestra, D., Faella, A., Margaritis, P., Cavallari, N., Pagani, F., Bernardi, F., Arruda, V. R., & Pinotti, M. (2014). An engineered U1 small nuclear RNA rescues splicing-defective coagulation F7 gene expression in mice. Journal of Thrombosis and Haemostasis, 12(2), 177-185. https://doi.org/10.1111/jth.12471
Balestra, D., Scalet, D., Ferrarese, M., Lombardi, S., Ziliotto, N., Croes, C. C., Petersen, N., Bosma, P., Riccardi, F., Pagani, F., Pinotti, M., & van de Graaf, S. F. J. (2020). A compensatory U1snRNA partially rescues FAH splicing and protein expression in a splicing-defective mouse model of tyrosinemia type I. International Journal of Molecular Sciences, 21(6), 2136. https://doi.org/10.3390/ijms21062136
Balestra, D., Scalet, D., Pagani, F., Rogalska, M. E., Mari, R., Bernardi, F., & Pinotti, M. (2016). An exon-specific U1snRNA induces a robust factor IX activity in mice expressing multiple human FIX splicing mutants. Molecular Therapy-Nucleic Acids, 5(10), e370. https://doi.org/10.1038/mtna.2016.77
Berg, A., Hallowell, S., Tibbetts, M., Beasley, C., Brown-Phillips, T., Healy, A., Pustilnik, L., Doyonnas, R., & Pregel, M. (2019). High-throughput surface liquid absorption and secretion assays to identify F508del CFTR correctors using patient primary airway epithelial cultures. SLAS Discovery, 24(7), 724-737. https://doi.org/10.1177/2472555219849375
De Boeck, K., & Amaral, M. D. (2016). Progress in therapies for cystic fibrosis. In The Lancet Respiratory Medicine (4, pp. 662-674. Lancet Publishing Group Issue 8. https://doi.org/10.1016/S2213-2600(16)00023-0
Boj, S. F., Vonk, A. M., Statia, M., Su, J., Vries, R. R. G., Beekman, J. M., & Clevers, H. (2017). Forskolin-induced swelling in intestinal organoids: An in vitro assay for assessing drug response in cystic fibrosis patients. Journal of Visualized Experiments, 2017(120). https://doi.org/10.3791/55159
Boyle, M. P., Bell, S. C., Konstan, M. W., McColley, S. A., Rowe, S. M., Rietschel, E., Huang, X., Waltz, D., Patel, N. R., & Rodman, D. (2014). A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: A phase 2 randomised controlled trial. The Lancet Respiratory Medicine, 2(7), 527-538. https://doi.org/10.1016/S2213-2600(14)70132-8
Boussaroque, A., Audrézet, M. P., Raynal, C., Sermet-Gaudelus, I., Bienvenu, T., Férec, C., Bergougnoux, A., Lopez, M., Scotet, V., Munck, A., & Girodon, E. (2020). Penetrance is a critical parameter for assessing the disease liability of CFTR variants. Journal of Cystic Fibrosis. Advance online publication. https://doi.org/10.1016/j.jcf.2020.03.019
Buratti, E., & Baralle, F. E. (2004). Influence of RNA secondary structure on the pre-mRNA splicing process. Molecular and Cellular Biology, 24(24), 10505-10514. https://doi.org/10.1128/mcb.24.24.10505-10514.2004
Buratti, E., Dörk, T., Zuccato, E., Pagani, F., Romano, M., & Baralle, F. E. (2001). Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO Journal, 20(7), 1774-1784. https://doi.org/10.1093/emboj/20.7.1774
Burgel, P. R., Bellis, G., Olesen, H. V., Viviani, L., Zolin, A., Blasi, F., Elborn, J. S., Bell, S., Castellani, C., Dembski, B., Drevinek, P., Heijerman, H., Innes, A., Lindblad, A., Madge, S., De Rijcke, K., & Solé, A. (2015). Future trends in cystic fibrosis demography in 34 European countries. European Respiratory Journal, 46(1), 133-141. https://doi.org/10.1183/09031936.00196314
Chaudary, N. (2018). Triplet CFTR modulators: Future prospects for treatment of cystic fibrosis. Therapeutics and Clinical Risk Management, 14, 2375-2383. https://doi.org/10.2147/TCRM.S147164
Choi, J. Y., Muallem, D., Kiselyov, K., Lee, M. G., Thomas, P. J., & Muallem, S. (2001). Aberrant CFTR-dependent HCO3- transport in mutations associated with cystic fibrosis. Nature, 410(6824), 94-97. https://doi.org/10.1038/35065099
Clancy, J. P. (2018). Rapid therapeutic advances in CFTR modulator science. Pediatric Pulmonology, 53(S3), S4-S11. https://doi.org/10.1002/ppul.24157
Cuppens, H., Lin, W., Jaspers, M., Costes, B., Teng, H., Vankeerberghen, A., Jorissen, M., Droogmans, G., Reynaert, I., Goosens, M., Nilius, B., & Cassiman, J. J. (1998). Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes: The polymorphic (TG)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. Journal of Clinical Investigation, 101(2), 487-496. https://doi.org/10.1172/JCI639
Dal Mas, A., Fortugno, P., Donadon, I., Levati, L., Castiglia, D., & Pagani, F. (2015a). Exon-specific U1s correct SPINK5 exon 11 skipping caused by a synonymous substitution that affects a bifunctional splicing regulatory element. Human Mutation, 36(5), 504-512. https://doi.org/10.1002/humu.22762
Dal Mas, A., Rogalska, M. E., Bussani, E., & Pagani, F. (2015b). Improvement of SMN2 pre-mRNA processing mediated by exon-specific U1 small nuclear RNA. American Journal of Human Genetics, 96(1), 93-103. https://doi.org/10.1016/j.ajhg.2014.12.009
Dekkers, J. F., Berkers, G., Kruisselbrink, E., Vonk, A., De Jonge, H. R., Janssens, H. M., Bronsveld, I., Van De Graaf, E. A., Nieuwenhuis, E. E. S., Houwen, R. H. J., Vleggaar, F. P., Escher, J. C., De Rijke, Y. B., Majoor, C. J., Heijerman, H. G. M., De Winter-De Groot, K. M., Clevers, H., Van Der Ent, C. K., & Beekman, J. M. (2016). Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis. Science Translational Medicine (8, pp. 344ra84). https://doi.org/10.1126/scitranslmed.aad8278
Dekkers, J. F., Wiegerinck, C. L., De Jonge, H. R., Bronsveld, I., Janssens, H. M., De Winter-De Groot, K. M., Brandsma, A. M., De Jong, N. W. M., Bijvelds, M. J. C., Scholte, B. J., Nieuwenhuis, E. E. S., Van Den Brink, S., Clevers, H., Van Der Ent, C. K., Middendorp, S., & Beekman, J. M. (2013). A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nature Medicine, 19(7), 939-945. https://doi.org/10.1038/nm.3201
den Dunnen, J. T., Dalgleish, R., Maglott, D. R., Hart, R. K., Greenblatt, M. S., Mcgowan-Jordan, J., Roux, A. F., Smith, T., Antonarakis, S. E., & Taschner, P. E. M. (2016). HGVS recommendations for the description of sequence variants: 2016 update. Human Mutation, 37(6), 564-569. https://doi.org/10.1002/humu.22981
Donadon, I., Bussani, E., Riccardi, F., Licastro, D., Romano, G., Pianigiani, G., Pinotti, M., Konstantinova, P., Evers, M., Lin, S., Rüegg, M. A., & Pagani, F. (2019). Rescue of spinal muscular atrophy mouse models with AAV9-Exon-specific U1 snRNA. Nucleic Acids Research, 47(14), 7618-7632. https://doi.org/10.1093/nar/gkz469
Donadon, I., Pinotti, M., Rajkowska, K., Pianigiani, G., Barbon, E., Morini, E., Motaln, H., Rogelj, B., Mingozzi, F., Slaugenhaupt, S. A., & Pagani, F. (2018). Exon-specific U1 snRNAs improve ELP1 exon 20 definition and rescue ELP1 protein expression in a familial dysautonomia mouse model. Human Molecular Genetics, 27(14), 2466-2476. https://doi.org/10.1093/hmg/ddy151
Du, Q., Li, Z., Pan, Y., Liu, X., Pan, B., & Wu, B. (2014). The CFTR M470V, intron 8 poly-T, and 8 TG-repeats detection in Chinese males with congenital bilateral absence of the vas deferens. BioMed Research International, 2014, 689185-689187. https://doi.org/10.1155/2014/689185
Dujardin, G., Commandeur, D., Le Jossic-Corcos, C., Ferec, C., & Corcos, L. (2011). Splicing defects in the CFTR gene: Minigene analysis of two mutations, 1811+1G>C and 1898+3A>G. Journal of Cystic Fibrosis, 10(3), 212-216. https://doi.org/10.1016/j.jcf.2010.12.008
Fajac, I., & Wainwright, C. E. (2017). New treatments targeting the basic defects in cystic fibrosis, Presse Medicale (46, pp. e165-e175). Elsevier Masson SAS Issue 6P2. https://doi.org/10.1016/j.lpm.2017.01.024
Farinha, C. M., & Matos, P. (2016). Repairing the basic defect in cystic fibrosis-One approach is not enough. FEBS Journal (283, pp. 246-264). Blackwell Publishing Ltd Issue 2. https://doi.org/10.1111/febs.13531
Farrell, P. M., White, T. B., Ren, C. L., Hempstead, S. E., Accurso, F., Derichs, N., Howenstine, M., McColley, S. A., Rock, M., Rosenfeld, M., Sermet-Gaudelus, I., Southern, K. W., Marshall, B. C., & Sosnay, P. R. (2017). Diagnosis of cystic fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. Journal of Pediatrics, 181, S4-S15. https://doi.org/10.1016/j.jpeds.2016.09.064
Gees, M., Musch, S., Van Der Plas, S., Wesse, A. S., Vandevelde, A., Verdonck, K., Mammoliti, O., Hwang, T. C., Sonck, K., Stouten, P., Swensen, A. M., Jans, M., Van Der Schueren, J., Nelles, L., Andrews, M., & Conrath, K. (2018). Identification and characterization of novel CFTR potentiators. Frontiers in Pharmacology, 9(OCT), 1221. https://doi.org/10.3389/fphar.2018.01221
Gentzsch, M., & Mall, M. A. (2018). Ion channel modulators in cystic fibrosis, Chest (154, pp. 383-393). Elsevier Inc. https://doi.org/10.1016/j.chest.2018.04.036
Ghosh, M., Ahmad, S., White, C. W., & Reynolds, S. D. (2017). Transplantation of airway epithelial stem/progenitor cells: A future for cell-based therapy. American Journal of Respiratory Cell and Molecular Biology, 56(1), 1-10. https://doi.org/10.1165/rcmb.2016-0181MA
Giuliano, K. A., Wachi, S., Drew, L., Dukovski, D., Green, O., Bastos, C., Cullen, M. D., Hauck, S., Tait, B. D., Munoz, B., Lee, P. S., & Miller, J. P. (2018). Use of a high-throughput phenotypic screening strategy to identify amplifiers, a novel pharmacological class of small molecules that exhibit functional synergy with potentiators and correctors. SLAS Discovery, 23(2), 111-121. https://doi.org/10.1177/2472555217729790
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A., Joubran, J., Hazlewood, A., Zhou, J., McCartney, J., Arumugam, V., Decker, C., Yang, J., Young, C., Olson, E. R., Wine, J. J., … Negulescu, P. (2009). Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proceedings of the National Academy of Sciences of the United States of America, 106(44), 18825-18830. https://doi.org/10.1073/pnas.0904709106
Gregory, R. J., Cheng, S. H., Rich, D. P., Marshall, J., Paul, S., Hehir, K., Ostedgaard, L., Klinger, K. W., Welsh, M. J., & Smith, A. E. (1990). Expression and characterization of the cystic fibrosis transmembrane conductance regulator. Nature, 347(6291), 382-386. https://doi.org/10.1038/347382a0
Groman, J. D., Hefferon, T. W., Casals, T., Bassas, L., Estivill, X., Des Georges, M., Guittard, C., Koudova, M., Fallin, M. D., Nemeth, K., Fekete, G., Kadasi, L., Friedman, K., Schwarz, M., Bombieri, C., Pignatti, P. F., Kanavakis, E., Tzetis, M., … Cutting, G. R. (2004). Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. American Journal of Human Genetics, 74(1), 176-179. https://doi.org/10.1086/381001
Gui, L., Qian, H., Rocco, K. A., Grecu, L., & Niklason, L. E. (2015). Efficient intratracheal delivery of airway epithelial cells in mice and pigs. American Journal of Physiology-Lung Cellular and Molecular Physiology, 308(2), L221-L228. https://doi.org/10.1152/ajplung.00147.2014
Guimbellot, J., Sharma, J., & Rowe, S. M. (2017). Toward inclusive therapy with CFTR modulators: Progress and challenges. Pediatric Pulmonology, 52(S48), S4-S14. https://doi.org/10.1002/ppul.23773
Hoy, S. M. (2019). Elexacaftor/ivacaftor/tezacaftor: First approval. Drugs, 79(18), 2001-2007. https://doi.org/10.1007/s40265-019-01233-7
Igreja, S., Clarke, L. A., Botelho, H. M., Marques, L., & Amaral, M. D. (2015). Correction of a cystic fibrosis splicing mutation by antisense oligonucleotides. Human Mutation, 37(2), 209-215. https://doi.org/10.1002/humu.22931
Kosorok, M. R., Wei, W. H., & Farrell, P. M. (1996). The incidence of cystic fibrosis. Statistics in Medicine, 15(5), 449-462. https://doi.org/10.1002/(SICI)1097-0258(19960315)15:5<449::AID-SIM173>3.0.CO;2-X
Liang, F., Shang, H., Jordan, N. J., Wong, E., Mercadante, D., Saltz, J., Mahiou, J., Bihler, H. J., & Mense, M. (2017). High-throughput screening for readthrough modulators of CFTR PTC Mutations. SLAS Technology, 22(3), 315-324. https://doi.org/10.1177/2472630317692561
Marcorelles, P., Friocourt, G., Uguen, A., Ledé, F., Férec, C., & Laquerrière, A. (2014). Cystic fibrosis transmembrane conductance regulator protein (CFTR) expression in the developing human brain: Comparative immunohistochemical study between patients with normal and mutated CFTR. Journal of Histochemistry and Cytochemistry, 62(11), 791-801. https://doi.org/10.1369/0022155414546190
Mattioli, C., Pianigiani, G., De Rocco, D., Bianco, A. M. R., Cappelli, E., Savoia, A., & Pagani, F. (2014). Unusual splice site mutations disrupt FANCA exon 8 definition. Biochimica et Biophysica Acta-Molecular Basis of Disease, 1842(7), 1052-1058. https://doi.org/10.1016/j.bbadis.2014.03.014
Merkert, S., Schubert, M., Olmer, R., Engels, L., Radetzki, S., Veltman, M., Scholte, B. J., Zöllner, J., Pedemonte, N., Galietta, L. J. V., von Kries, J. P., & Martin, U. (2019). High-throughput screening for modulators of CFTR activity based on genetically engineered cystic fibrosis disease-specific iPSCs. Stem Cell Reports, 12(6), 1389-1403. https://doi.org/10.1016/j.stemcr.2019.04.014
Nizzardo, M., Simone, C., Dametti, S., Salani, S., Ulzi, G., Pagliarani, S., Rizzo, F., Frattini, E., Pagani, F., Bresolin, N., Comi, G., & Corti, S. (2015). Spinal muscular atrophy phenotype is ameliorated in human motor neurons by SMN increase via different novel RNA therapeutic approaches. Scientific Reports, 5, 11746. https://doi.org/10.1038/srep11746
Ohkubo, A., Kondo, Y., Suzuki, M., Kobayashi, H., Kanamori, T., Masaki, Y., Seio, K., Nagai, K., & Sekine, M. (2013). Chemical synthesis of U1 snRNA derivatives. Organic Letters, 15(17), 4386-4389. https://doi.org/10.1021/ol401917r
Ontalus, V., Cobianu, C., Vasiliu, F., & Parlog, C. (1996). Crystallization behaviour and phase coexistence at morphotrophic phase boundaries in PZT thin films prepared by sol-gel processing. Journal of Materials Science, 31(14), 3639-3642. https://doi.org/10.1007/BF00352771
Pagani, F., Buratti, E., Stuani, C., & Baralle, F. E. (2003). Missense, nonsense, and neutral mutations define juxtaposed regulatory elements of splicing in cystic fibrosis transmembrane regulator exon 9. Journal of Biological Chemistry, 278(29), 26580-26588. https://doi.org/10.1074/jbc.M212813200
Pagani, F., Buratti, E., Stuani, C., Bendix, R., Dörk, T., & Baralle, F. E. (2002). A new type of mutation causes a splicing defect in ATM. Nature Genetics, 30(4), 426-429. https://doi.org/10.1038/ng858
Pagani, F., Buratti, E., Stuani, C., Romano, M., Zuccato, E., Niksic, M., Giglio, L., Faraguna, D., & Baralle, F. E. (2000). Splicing factors induce cystic fibrosis transmembrane regulator exon 9 skipping through a nonevolutionary conserved intronic element. Journal of Biological Chemistry, 275(28), 21041-21047. https://doi.org/10.1074/jbc.M910165199
Palomaki, G. E., Fitzsimmons, S. C., & Haddow, J. E. (2004). Clinical sensitivity of prenatal screening for cystic fibrosis via CFTR carrier testing in a United States panethnic population. Genetics in Medicine, 6(5), 405-414. https://doi.org/10.1097/01.GIM.0000139505.06194.39
Paranjape, S. M., & Mogayzel, P. J. (2018). Cystic fibrosis in the era of precision medicine, Paediatric Respiratory Reviews (25, pp. 64-72). W.B. Saunders Ltd.
Pereira, S. V. N., Ribeiro, J. D., Ribeiro, A. F., Bertuzzo, C. S., & Marson, F. A. L. (2019). Novel, rare and common pathogenic variants in the CFTR gene screened by high-throughput sequencing technology and predicted by in silico tools. Scientific Reports, 9(1), 6234. https://doi.org/10.1038/s41598-019-42404-6
Phuan, P. W., Son, J. H., Tan, J. A., Li, C., Musante, I., Zlock, L., Nielson, D. W., Finkbeiner, W. E., Kurth, M. J., Galietta, L. J., Haggie, P. M., & Verkman, A. S. (2018). Combination potentiator (‘co-potentiator’) therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators. Journal of Cystic Fibrosis, 17(5), 595-606. https://doi.org/10.1016/j.jcf.2018.05.010
Pranke, I. M., Golec, A., Hinzpeter, A., Edelman, A., & Sermet-Gaudelus, I. (2019). Emerging therapeutic approaches for cystic fibrosis. From gene editing to personalized medicine, Frontiers in Pharmacology (10). Frontiers Media S.A. Issue FEB)
Pranke, I. M., Hatton, A., Simonin, J., Jais, J. P., Le Pimpec-Barthes, F., Carsin, A., Bonnette, P., Fayon, M., Stremler-Le Bel, N., Grenet, D., Thumerel, M., Mazenq, J., Urbach, V., Mesbahi, M., Girodon-Boulandet, E., Hinzpeter, A., Edelman, A., & Sermet-Gaudelus, I. (2017). Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators. Scientific Reports, 7(1), 1-11. https://doi.org/10.1038/s41598-017-07504-1
Rogalska, M. E., Tajnik, M., Licastro, D., Bussani, E., Camparini, L., Mattioli, C., & Pagani, F. (2016). Therapeutic activity of modified U1 core spliceosomal particles. Nature. Communications, 7, 1-13. https://doi.org/10.1038/ncomms11168
Roomans, G. M. (2014). Pharmacological treatment of the basic defect in cystic fibrosis. Cell Biology International, 38(11), 1244-1246. https://doi.org/10.1002/cbin.10312
Rosen, C., Shezen, E., Aronovich, A., Klionsky, Y. Z., Yaakov, Y., Assayag, M., Biton, I. E., Tal, O., Shakhar, G., Ben-Hur, H., Shneider, D., Vaknin, Z., Sadan, O., Evron, S., Freud, E., Shoseyov, D., Wilschanski, M., Berkman, N., Fibbe, W. E., … Reisner, Y. (2015). Preconditioning allows engraftment of mouse and human embryonic lung cells, enabling lung repair in mice. Nature Medicine, 21(8), 869-879. https://doi.org/10.1038/nm.3889
Sato, T., Stange, D. E., Ferrante, M., Vries, R. G. J., Van Es, J. H., Van Den Brink, S., Van Houdt, W. J., Pronk, A., Van Gorp, J., Siersema, P. D., & Clevers, H. (2011). Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology, 141(5), 1762-1772. https://doi.org/10.1053/j.gastro.2011.07.050
Sato, T., Vries, R. G., Snippert, H. J., Van De Wetering, M., Barker, N., Stange, D. E., Van Es, J. H., Abo, A., Kujala, P., Peters, P. J., & Clevers, H. (2009). Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature, 459(7244), 262-265. https://doi.org/10.1038/nature07935
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012). NIH Image to ImageJ: 25 years of image analysis. Nature Methods, 9(7), 671-675. https://doi.org/10.1038/nmeth.2089
Schram, C. A. (2012). Atypical cystic fibrosis: Identification in the primary care setting. Canadian Family Physician Medecin de famille canadien, 58(12), 1341-1345, e699-704. http://www.ncbi.nlm.nih.gov/pubmed/23242890.
Strug, L. J., Stephenson, A. L., Panjwani, N., & Harris, A. (2018). Recent advances in developing therapeutics cibrosis. CMolecular Genetics, 27(R2), R173-R186. https://doi.org/10.1093/hmg/ddy188
Suñé-Pou, M., Limeres, M. J., Moreno-Castro, C., Hernández-Munain, C., Suñé-Negre, J. M., Cuestas, M. L., & Suñé, C. (2020). Innovative therapeutic and delivery approaches using nanotechnology to correct splicing defects underlying diseasefrontiers in genetics (11, p. 731). Frontiers Media S.A. https://doi.org/10.3389/fgene.2020.00731
Tajnik, M., Rogalska, M. E., Bussani, E., Barbon, E., Balestra, D., Pinotti, M., & Pagani, F. (2016). Molecular basis and therapeutic strategies to rescue factor ix variants that affect splicing and protein function. PLoS Genetics, 12(5), 1-16. https://doi.org/10.1371/journal.pgen.1006082
Wang, P., Lin, Z., Su, X., & Tang, Z. (2017). Application of Au based nanomaterials in analytical science. Nano Today, 12(13), 64-97. https://doi.org/10.1016/j.nantod.2016.12.009
Wu, H., Zhu, M., Xiong, X., Wei, J., Zhuo, K., & Cheng, D. (2019). Efficacy and safety of CFTR corrector and potentiator combination therapy in patients with cystic fibrosis for the F508del-CFTR homozygous mutation: a systematic review and meta-analysis. Advances in Therapy, 36(2), 451-461. https://doi.org/10.1007/s12325-018-0860-4
Yeh, H. I., Sohma, Y., Conrath, K., & Hwang, T. C. (2017). A common mechanism for CFTR potentiators. Journal of General Physiology, 149(12), 1105-1118. https://doi.org/10.1085/jgp.201711886
Zielenski, J. (2000). Genotype and phenotype in cystic fibrosis. Respiration (67, pp. 117-133). S. Karger AG. https://doi.org/10.1159/000029497
Zuccato, E., Buratti, E., Stuani, C., Baralle, F. E., & Pagani, F. (2004). An intronic polypyrimidine-rich element downstream of the donor site modulates cystic fibrosis transmembrane conductance regulator exon 9 alternative splicing. Journal of Biological Chemistry, 279(17), 16980-16988. https://doi.org/10.1074/jbc.M313439200
Zuker, M. (2003). Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Research, 31(13), 3406-3415. https://doi.org/10.1093/nar/gkg595
Zychlinski, D., Erkelenz, S., Melhorn, V., Baum, C., Schaal, H., & Bohne, J. (2009). Limited complementarity between U1 snRNA and a retroviral 5′ splice site permits its attenuation via RNA secondary structure. Nucleic Acids Research, 37(22), 7429-7440. https://doi.org/10.1093/nar/gkp694